Shopping Cart
Remove All
Your shopping cart is currently empty
Abatacept
(Synonyms: CTLA4lg, BMS-188667) Copy Product Info
🥰Excellent
Synonyms: CTLA4lg, BMS-188667
Catalog No. T10218 Copy Product Info
Purity: 95%
🥰Excellent
Abatacept is a soluble recombinant fusion protein, which consists of extracellular domain of human CTLA-4 and human Fc segment. Abatacept specifically blocks CD28-mediated costimulatory signals by binding to CD80 and CD86 on the surface of antigen presenting cells with high affinity, thus inhibiting T cell activation. Abatacept is often used to study rheumatoid arthritis, autoimmune reaction and immune disorder caused by LRBA deficiency.
Cas No. 332348-12-6
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 5 mg | $813 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Chemical Properties
Storage & Solubility Information
| Description | Abatacept is a soluble recombinant fusion protein, which consists of extracellular domain of human CTLA-4 and human Fc segment. Abatacept specifically blocks CD28-mediated costimulatory signals by binding to CD80 and CD86 on the surface of antigen presenting cells with high affinity, thus inhibiting T cell activation. Abatacept is often used to study rheumatoid arthritis, autoimmune reaction and immune disorder caused by LRBA deficiency. |
| In vitro | In co-culture assays of primary CD4+ T cells and APCs, Abatacept (100 ug/mL) blocked the CD80/86:CD28 costimulatory axis and inhibited T-cell proliferation [3]. In ex vivo analysis of cells from patients with LRBA deficiency, Abatacept modulated CTLA-4 expression levels and restored regulatory T cell function [1]. |
| In vivo | In a rat model of collagen-induced arthritis, subcutaneous administration of Abatacept (0.1, 1, 10 mg/kg) led to dose-dependent reduction in paw edema [2]. In mouse T-cell priming models, systemic administration of Abatacept (0.5 mg/mouse) inhibited antigen-specific T-cell activation and expansion [3]. |
| Synonyms | CTLA4lg, BMS-188667 |
| Animal Research | Animal Model: Male Lewis rats (6-9 weeks old) with weights of 150-175 g. Dosage: 10 mg/kg (i.v.), 20 mg/kg (s.c. single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29. Administration: i.v. or s.c. [2] |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 332348-12-6 |
| Relative Density. | no data available |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Keywords
Preview
Related Tags: Abatacept chemical structure | Abatacept in vivo | Abatacept in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.